Trials / Unknown
UnknownNCT06151249
Evaluate the Meritup Oral Solution to Decrease Fatigue in Metastatic Breast Cancer Patients Receiving Chemotherapy
A Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Safety and Ability of Meritup Oral Liquid to Reduce Fatigue in Patients With Metastatic Breast Cancer Receiving Chemotherapy
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 32 (estimated)
- Sponsor
- Chung Shan Medical University · Academic / Other
- Sex
- Female
- Age
- 20 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
A randomized, double-blind, placebo-controlled, parallel study to evaluate the safety profile and ability of Meritup oral solution to decrease fatigue in metastatic breast cancer patients receiving chemotherapy.
Detailed description
The study population designed to be enrolled is patients with histologically and/or cytologically confirmed breast cancer with clinical evidence of recurrent or progressive metastatic disease and at least completed 3 cycle chemotherapy regimen who have evidence of fatigue.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| COMBINATION_PRODUCT | Meritup oral solution | chemotherapy + Meritup |
Timeline
- Start date
- 2023-12-01
- Primary completion
- 2025-11-30
- Completion
- 2025-11-30
- First posted
- 2023-11-30
- Last updated
- 2023-11-30
Source: ClinicalTrials.gov record NCT06151249. Inclusion in this directory is not an endorsement.